Research and Clinical Trials
Mid Florida Eye’s selection to participate in national clinical trials allows us to offer our patients access to the most revolutionary research for advanced diagnostic and treatment options available.
Our physicians have participated in multiple clinical trials, with new studies on the horizon.
These clinical trials are a crucial component in developing new, more-effective sight-saving and sight-prolonging diagnostic techniques and treatments. Many of today’s gold-standard therapies are based on the results of previous trials, such as those we’ve conducted for the treatment of macular degeneration, glaucoma, cataracts and other conditions.
A clinical trial may be the best way for individuals to get the most-advanced, leading-edge treatment. Patients have access to new drugs and treatments before they are widely available, and because controlling and recording all factors is critical to the trial’s success, participants get excellent attention and are closely monitored and cared for.
Participation in a clinical trial is completely voluntary. Criteria for study participantion is very stringent, and some people may not be eligible for participation.
We strive to provide our study patients with the best medical care possible. Should you wish to participate in any clinical trial, please discuss this with your physician.
Participants may be entitled to receive the some or all of the following at no cost.
- Exam(s) by physician
- Lab work
- Frequent checkups
- Medications
- Travel reimbursement
- New Custom Cataract Lens Implant
HAVE CATARACTS AND AGE-RELATED MACULAR DEGENERATION (AMD)?
Mid Florida Eye Center is looking for individuals who have been diagnosed with cataracts and AMD to participate in a clinical investigation. The study involves a new investigational intraocular lens that is designed to provide near and far vision with increased independence of low vision aids. If you are at least 55 years old, and need cataract surgery for either eye, please contact: Laura at 352-735-2020 x 147.